Literature DB >> 28490495

Exclusion of alternative exon 33 of CaV1.2 calcium channels in heart is proarrhythmogenic.

Guang Li1,2, Juejin Wang1,3, Ping Liao4, Peter Bartels1, Hengyu Zhang1, Dejie Yu1, Mui Cheng Liang1, Kian Keong Poh5, Chye Yun Yu4, Fengli Jiang1, Tan Fong Yong1, Yuk Peng Wong1, Zhenyu Hu1, Hua Huang1, Guangqin Zhang6, Mary Joyce Galupo5, Jin-Song Bian7, Sathivel Ponniah8, Scott Lee Trasti9, Kelvin See10, Roger Foo10, Uta C Hoppe11, Stefan Herzig12,13, Tuck Wah Soong14,4,15,16.   

Abstract

Alternative splicing changes the CaV1.2 calcium channel electrophysiological property, but the in vivo significance of such altered channel function is lacking. Structure-function studies of heterologously expressed CaV1.2 channels could not recapitulate channel function in the native milieu of the cardiomyocyte. To address this gap in knowledge, we investigated the role of alternative exon 33 of the CaV1.2 calcium channel in heart function. Exclusion of exon 33 in CaV1.2 channels has been reported to shift the activation potential -10.4 mV to the hyperpolarized direction, and increased expression of CaV1.2Δ33 channels was observed in rat myocardial infarcted hearts. However, how a change in CaV1.2 channel electrophysiological property, due to alternative splicing, might affect cardiac function in vivo is unknown. To address these questions, we generated mCacna1c exon 33-/--null mice. These mice contained CaV1.2Δ33 channels with a gain-of-function that included conduction of larger currents that reflects a shift in voltage dependence and a modest increase in single-channel open probability. This altered channel property underscored the development of ventricular arrhythmia, which is reflected in significantly more deaths of exon 33-/- mice from β-adrenergic stimulation. In vivo telemetric recordings also confirmed increased frequencies in premature ventricular contractions, tachycardia, and lengthened QT interval. Taken together, the significant decrease or absence of exon 33-containing CaV1.2 channels is potentially proarrhythmic in the heart. Of clinical relevance, human ischemic and dilated cardiomyopathy hearts showed increased inclusion of exon 33. However, the possible role that inclusion of exon 33 in CaV1.2 channels may play in the pathogenesis of human heart failure remains unclear.

Entities:  

Keywords:  CaV1.2 channel; alternative splicing; cardiac arrhythmia; cardiac function; heart failure

Mesh:

Substances:

Year:  2017        PMID: 28490495      PMCID: PMC5448171          DOI: 10.1073/pnas.1617205114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  50 in total

Review 1.  Remodeled cardiac calcium channels.

Authors:  Geoffrey S Pitt; Wen Dun; Penelope A Boyden
Journal:  J Mol Cell Cardiol       Date:  2006-08-08       Impact factor: 5.000

Review 2.  Dynamics of human atrial cell models: restitution, memory, and intracellular calcium dynamics in single cells.

Authors:  Elizabeth M Cherry; Harold M Hastings; Steven J Evans
Journal:  Prog Biophys Mol Biol       Date:  2008-05-29       Impact factor: 3.667

3.  RBFOX1 regulates both splicing and transcriptional networks in human neuronal development.

Authors:  Brent L Fogel; Eric Wexler; Amanda Wahnich; Tara Friedrich; Chandran Vijayendran; Fuying Gao; Neelroop Parikshak; Genevieve Konopka; Daniel H Geschwind
Journal:  Hum Mol Genet       Date:  2012-06-23       Impact factor: 6.150

4.  In vivo cardiac electrophysiology studies in the mouse.

Authors:  C I Berul; M J Aronovitz; P J Wang; M E Mendelsohn
Journal:  Circulation       Date:  1996-11-15       Impact factor: 29.690

5.  Shaping a new Ca²⁺ conductance to suppress early afterdepolarizations in cardiac myocytes.

Authors:  Roshni V Madhvani; Yuanfang Xie; Antonios Pantazis; Alan Garfinkel; Zhilin Qu; James N Weiss; Riccardo Olcese
Journal:  J Physiol       Date:  2011-10-24       Impact factor: 5.182

6.  Neuronal L-type calcium channels open quickly and are inhibited slowly.

Authors:  Thomas D Helton; Weifeng Xu; Diane Lipscombe
Journal:  J Neurosci       Date:  2005-11-02       Impact factor: 6.167

7.  Cardiac dysfunction in hypertrophic cardiomyopathy mutant tropomyosin mice is transgene-dependent, hypertrophy-independent, and improved by beta-blockade.

Authors:  Daniel E Michele; Carlen A Gomez; Katie E Hong; Margaret V Westfall; Joseph M Metzger
Journal:  Circ Res       Date:  2002-08-09       Impact factor: 17.367

8.  Diastolic intracellular calcium-membrane voltage coupling gain and postshock arrhythmias: role of purkinje fibers and triggered activity.

Authors:  Mitsunori Maruyama; Boyoung Joung; Liang Tang; Tetsuji Shinohara; Young-Keun On; Seongwook Han; Eue-Keun Choi; Dae-Hyeok Kim; Mark J Shen; James N Weiss; Shien-Fong Lin; Peng-Sheng Chen
Journal:  Circ Res       Date:  2009-11-19       Impact factor: 17.367

9.  Single-channel gating and regulation of human L-type calcium channels in cardiomyocytes of transgenic mice.

Authors:  Ferdi Groner; Marta Rubio; Patrick Schulte-Euler; Jan Matthes; Ismail F Y Khan; Ilona Bodi; Sheryl E Koch; Arnold Schwartz; Stefan Herzig
Journal:  Biochem Biophys Res Commun       Date:  2004-02-13       Impact factor: 3.575

Review 10.  Echocardiography in translational research: of mice and men.

Authors:  Marielle Scherrer-Crosbie; Helène B Thibault
Journal:  J Am Soc Echocardiogr       Date:  2008-08-23       Impact factor: 5.251

View more
  16 in total

1.  Aberrant Expression of a Non-muscle RBFOX2 Isoform Triggers Cardiac Conduction Defects in Myotonic Dystrophy.

Authors:  Chaitali Misra; Sushant Bangru; Feikai Lin; Kin Lam; Sara N Koenig; Ellen R Lubbers; Jamila Hedhli; Nathaniel P Murphy; Darren J Parker; Lawrence W Dobrucki; Thomas A Cooper; Emad Tajkhorshid; Peter J Mohler; Auinash Kalsotra
Journal:  Dev Cell       Date:  2020-02-27       Impact factor: 12.270

Review 2.  Alternative splicing isoforms in health and disease.

Authors:  Hyoung Kyu Kim; Michael Huy Cuong Pham; Kyung Soo Ko; Byoung Doo Rhee; Jin Han
Journal:  Pflugers Arch       Date:  2018-03-13       Impact factor: 3.657

3.  Alternative Splicing at N Terminus and Domain I Modulates CaV1.2 Inactivation and Surface Expression.

Authors:  Peter Bartels; Dejie Yu; Hua Huang; Zhenyu Hu; Stefan Herzig; Tuck Wah Soong
Journal:  Biophys J       Date:  2018-05-08       Impact factor: 4.033

Review 4.  The physiology of alternative splicing.

Authors:  Luciano E Marasco; Alberto R Kornblihtt
Journal:  Nat Rev Mol Cell Biol       Date:  2022-10-13       Impact factor: 113.915

5.  The road to the brain in Timothy syndrome is paved with enhanced CaV1.2 activation gating.

Authors:  Laurent Ferron; Gerald W Zamponi
Journal:  J Gen Physiol       Date:  2022-10-20       Impact factor: 4.000

6.  Characterization of CaV1.2 exon 33 heterozygous knockout mice and negative correlation between Rbfox1 and CaV1.2 exon 33 expressions in human heart failure.

Authors:  Juejin Wang; Guang Li; Dejie Yu; Yuk Peng Wong; Tan Fong Yong; Mui Cheng Liang; Ping Liao; Roger Foo; Uta C Hoppe; Tuck Wah Soong
Journal:  Channels (Austin)       Date:  2018-01-01       Impact factor: 2.581

Review 7.  Alternative Splicing of L-type CaV1.2 Calcium Channels: Implications in Cardiovascular Diseases.

Authors:  Zhenyu Hu; Mui Cheng Liang; Tuck Wah Soong
Journal:  Genes (Basel)       Date:  2017-11-24       Impact factor: 4.096

Review 8.  Mutations in voltage-gated L-type calcium channel: implications in cardiac arrhythmia.

Authors:  Qing Zhang; Junjie Chen; Yao Qin; Juejin Wang; Lei Zhou
Journal:  Channels (Austin)       Date:  2018       Impact factor: 2.581

Review 9.  L-type voltage-gated calcium channels in stem cells and tissue engineering.

Authors:  Yi-Zhou Tan; Dong-Dong Fei; Xiao-Ning He; Ji-Min Dai; Rong-Chen Xu; Xin-Yue Xu; Jun-Jie Wu; Bei Li
Journal:  Cell Prolif       Date:  2019-05-21       Impact factor: 6.831

10.  Differential regulation of Cav2.2 channel exon 37 variants by alternatively spliced μ-opioid receptors.

Authors:  Maria A Gandini; Ivana A Souza; Dvij Raval; Jin Xu; Ying-Xian Pan; Gerald W Zamponi
Journal:  Mol Brain       Date:  2019-11-27       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.